Sino Biopharmaceutical Ltd - Company Profile
Powered by 
All the data and insights you need on Sino Biopharmaceutical Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Sino Biopharmaceutical Ltd Strategy Report
- Understand Sino Biopharmaceutical Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Sino Biopharmaceutical Ltd (Sino Biopharma), a subsidiary of Charoen Pokphand Group Co Ltd, is a research-oriented pharmaceutical company that develops, manufactures, and markets medicines, biopharmaceuticals, and Chinese medicines. It offers medicines for the treatment of hepatitis, cardio-cerebral diseases, cancer, orthopedic conditions, infectious diseases and respiratory and digestive diseases, among others. The company offers products in various dosage forms including large-volume injections, PVC-free soft bags for intravenous injections, small-volume injections, powdered medicines, granulated medicines, capsules, and tablets. It works in partnership with several domestic and foreign pharmaceutical companies to advance the development of its products. Sino Biopharma is headquartered in Wanchai, Hong Kong.
Headquarters
Hong Kong
Address
Unit 09, 41f, Office Tower, Convention Plaza, No. 1 Harbour Road, Wanchai, Hong Kong
Website
www.sinobiopharm.com
Telephone
852 28029886
No of Employees
25,806
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
1177 (HKG)
Revenue (2022)
$3.7B
-9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-8.3%
(2022 vs 2021)
Market Cap*
$6.5B
Net Profit Margin (2022)
XYZ
0.7%
(2022 vs 2021)
* As of and is in US$
Sino Biopharmaceutical Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Hepatitis Medicines: | Jiuli |
| Diammonium Glycyrrhizinate Enteric-coated Capsules | Tianjie |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In April, the company signed a strategic partnership with Boehringer Ingelheim to launch Boehringer Ingelheim’s innovative cancer therapies to the market in mainland China. |
| 2024 | Regulatory Approval | In March, the company received approval from the National Medical Products Administration of China for marketing the Iopromide Injection. |
| 2024 | Plans/Strategy | In February, the company announced plans to divest a 67% stake in unit CP Pharmaceutical (Qingdao) for US$253.28 million. |
Competitor Comparison
| Key Parameters | Sino Biopharmaceutical Ltd | China Resources Pharmaceutical Group Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Jiangsu Hengrui Medicine Co Ltd | The United Laboratories International Holdings Ltd |
|---|---|---|---|---|---|
| Headquarters | Hong Kong | Hong Kong | China | China | Hong Kong |
| City | Hong Kong | Hong Kong | Shanghai | Lianyungang | Yuen Long |
| State/Province | - | - | Shanghai | Jiangsu | - |
| No. of Employees | 25,806 | 72,986 | 40,370 | 20,636 | 15,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Tse, Eric S Y | Director; Chief Executive Officer | Executive Board | 2022 | 27 |
| Tse Ping | Senior Vice Chairman | Executive Board | 2020 | 71 |
| Theresa Tse | Chairwoman | Executive Board | 2015 | 30 |
| Sean Chen | Chief Strategy Officer | Senior Management | - | - |
| Cheng Cheung Ling | Director; Vice Chairman | Executive Board | - | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward